TY  - JOUR
AU  - Seferović, Jelena
AU  - Lalić, Nebojša M.
AU  - Floridi, Federico
AU  - Tesić, Milorad
AU  - Seferović, Petar M.
AU  - Giga, Vojislav
AU  - Lalić, Katarina
AU  - Jotić, Aleksandra
AU  - Jovičić, Snežana
AU  - Colak, Emina
AU  - Salerno, Gerardo
AU  - Cardelli, Patrizia
AU  - Di Somma, Salvatore
PY  - 2014
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2074
AB  - Background: Galectin-3 is a protein widely distributed in the heart, brain and blood vessels, and has a regulatory role in inflammation, immunology and cancer. Many studies demonstrated that the increased level of galectin-3 is associated with progressive fibrosis and stiffening of the myocardium. The aim of this study was to investigate the role of galectin-3 in patients with type 2 diabetes (T2D) and/or arterial hypertension (HT). Methods: Study population included 189 patients, with no coronary artery disease, divided into three groups: group 1 (T2D), group 2 (T2D+HT), and group 3 (HT). All subjects underwent routine laboratory tests, as well as specific biomarkers assessment [galectin-3, glycosylated hemoglobin (HbA(1c)), N- terminal fragment B-type natriuretic peptide (NT-proBNP)]. Cardiological evaluation included physical examination, transthoracic tissue Doppler echocardiography and stress echocardiography. Results: The results of this study demonstrated significantly increased levels of galectin-3, blood glucose, and HbA(1c) in group 2. Also, echocardiographicaly, left ventricular (LV) diameters and IVS thickness were increased in this group of patients. Furthermore, in the same cohort a positive correlation between galectin-3 and NT-pro BNP, and galectin-3 and LV mass were demonstrated. In addition, a negative correlation between galectin-3 and LV end-diastolic diameter was revealed. Conclusions: This study revealed that levels of galectin-3 were higher in patients with both T2D and HT, and correlated with LV mass, indicating the potential role of this biomarker for early detection of myocardial structural and functional alterations.
PB  - Walter de Gruyter Gmbh, Berlin
T2  - Clinical Chemistry and Laboratory Medicine
T1  - Structural myocardial alterations in diabetes and hypertension: the role of galectin-3
VL  - 52
IS  - 10
SP  - 1499
EP  - 1505
DO  - 10.1515/cclm-2014-0265
ER  - 

@article{
author = "Seferović, Jelena and Lalić, Nebojša M. and Floridi, Federico and Tesić, Milorad and Seferović, Petar M. and Giga, Vojislav and Lalić, Katarina and Jotić, Aleksandra and Jovičić, Snežana and Colak, Emina and Salerno, Gerardo and Cardelli, Patrizia and Di Somma, Salvatore",
year = "2014",
abstract = "Background: Galectin-3 is a protein widely distributed in the heart, brain and blood vessels, and has a regulatory role in inflammation, immunology and cancer. Many studies demonstrated that the increased level of galectin-3 is associated with progressive fibrosis and stiffening of the myocardium. The aim of this study was to investigate the role of galectin-3 in patients with type 2 diabetes (T2D) and/or arterial hypertension (HT). Methods: Study population included 189 patients, with no coronary artery disease, divided into three groups: group 1 (T2D), group 2 (T2D+HT), and group 3 (HT). All subjects underwent routine laboratory tests, as well as specific biomarkers assessment [galectin-3, glycosylated hemoglobin (HbA(1c)), N- terminal fragment B-type natriuretic peptide (NT-proBNP)]. Cardiological evaluation included physical examination, transthoracic tissue Doppler echocardiography and stress echocardiography. Results: The results of this study demonstrated significantly increased levels of galectin-3, blood glucose, and HbA(1c) in group 2. Also, echocardiographicaly, left ventricular (LV) diameters and IVS thickness were increased in this group of patients. Furthermore, in the same cohort a positive correlation between galectin-3 and NT-pro BNP, and galectin-3 and LV mass were demonstrated. In addition, a negative correlation between galectin-3 and LV end-diastolic diameter was revealed. Conclusions: This study revealed that levels of galectin-3 were higher in patients with both T2D and HT, and correlated with LV mass, indicating the potential role of this biomarker for early detection of myocardial structural and functional alterations.",
publisher = "Walter de Gruyter Gmbh, Berlin",
journal = "Clinical Chemistry and Laboratory Medicine",
title = "Structural myocardial alterations in diabetes and hypertension: the role of galectin-3",
volume = "52",
number = "10",
pages = "1499-1505",
doi = "10.1515/cclm-2014-0265"
}

Seferović, J., Lalić, N. M., Floridi, F., Tesić, M., Seferović, P. M., Giga, V., Lalić, K., Jotić, A., Jovičić, S., Colak, E., Salerno, G., Cardelli, P.,& Di Somma, S.. (2014). Structural myocardial alterations in diabetes and hypertension: the role of galectin-3. in Clinical Chemistry and Laboratory Medicine
Walter de Gruyter Gmbh, Berlin., 52(10), 1499-1505.
https://doi.org/10.1515/cclm-2014-0265

Seferović J, Lalić NM, Floridi F, Tesić M, Seferović PM, Giga V, Lalić K, Jotić A, Jovičić S, Colak E, Salerno G, Cardelli P, Di Somma S. Structural myocardial alterations in diabetes and hypertension: the role of galectin-3. in Clinical Chemistry and Laboratory Medicine. 2014;52(10):1499-1505.
doi:10.1515/cclm-2014-0265 .

Seferović, Jelena, Lalić, Nebojša M., Floridi, Federico, Tesić, Milorad, Seferović, Petar M., Giga, Vojislav, Lalić, Katarina, Jotić, Aleksandra, Jovičić, Snežana, Colak, Emina, Salerno, Gerardo, Cardelli, Patrizia, Di Somma, Salvatore, "Structural myocardial alterations in diabetes and hypertension: the role of galectin-3" in Clinical Chemistry and Laboratory Medicine, 52, no. 10 (2014):1499-1505,
https://doi.org/10.1515/cclm-2014-0265 . .

TY  - JOUR
AU  - Becarević, Mirjana
AU  - Seferović, Jelena
AU  - Ignjatović, Svetlana
AU  - Singh, Sandra
AU  - Majkić-Singh, Nada
PY  - 2012
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1756
AB  - The importance of the association of antiphospholipid antibodies (aPL Abs) with the features of type II diabetes mellitus has not yet been elucidated. The aim of this work was to investigate the association of aPL Abs with adiponectin and non-esterified fatty acids (NEFA) in type II diabetes mellitus patients without micro and/or macrovascular complications, and to analyze the differences between the male and female patients with regard to the abovementioned parameters. Male patients with type II diabetes mellitus showed a positive correlation between NEFA concentrations and anti-oxLDL antibodies (r = 0.334, p = 0.019). A weak, but statistically significant correlation between adiponectin concentrations and the IgM isotype of anti-annexin A5 antibodies was found in type II diabetes mellitus patients (r = 0.285, p = 0.011). The presence of a positive correlation between NEFA and anti-oxLDL antibodies might be useful in the detection of patients with premature atherosclerosis in type II diabetes mellitus patients without any micro and/or macrovascular complications among type II diabetes mellitus patients.
PB  - Društvo medicinskih biohemičara Srbije, Beograd i Versita
T2  - Journal of Medical Biochemistry
T1  - Adiponectin, non-esterified fatty acids and antiphospholipid antibodies in type II diabetes mellitus
VL  - 31
IS  - 3
SP  - 199
EP  - 204
DO  - 10.2478/v10011-012-0009-y
ER  - 

@article{
author = "Becarević, Mirjana and Seferović, Jelena and Ignjatović, Svetlana and Singh, Sandra and Majkić-Singh, Nada",
year = "2012",
abstract = "The importance of the association of antiphospholipid antibodies (aPL Abs) with the features of type II diabetes mellitus has not yet been elucidated. The aim of this work was to investigate the association of aPL Abs with adiponectin and non-esterified fatty acids (NEFA) in type II diabetes mellitus patients without micro and/or macrovascular complications, and to analyze the differences between the male and female patients with regard to the abovementioned parameters. Male patients with type II diabetes mellitus showed a positive correlation between NEFA concentrations and anti-oxLDL antibodies (r = 0.334, p = 0.019). A weak, but statistically significant correlation between adiponectin concentrations and the IgM isotype of anti-annexin A5 antibodies was found in type II diabetes mellitus patients (r = 0.285, p = 0.011). The presence of a positive correlation between NEFA and anti-oxLDL antibodies might be useful in the detection of patients with premature atherosclerosis in type II diabetes mellitus patients without any micro and/or macrovascular complications among type II diabetes mellitus patients.",
publisher = "Društvo medicinskih biohemičara Srbije, Beograd i Versita",
journal = "Journal of Medical Biochemistry",
title = "Adiponectin, non-esterified fatty acids and antiphospholipid antibodies in type II diabetes mellitus",
volume = "31",
number = "3",
pages = "199-204",
doi = "10.2478/v10011-012-0009-y"
}

Becarević, M., Seferović, J., Ignjatović, S., Singh, S.,& Majkić-Singh, N.. (2012). Adiponectin, non-esterified fatty acids and antiphospholipid antibodies in type II diabetes mellitus. in Journal of Medical Biochemistry
Društvo medicinskih biohemičara Srbije, Beograd i Versita., 31(3), 199-204.
https://doi.org/10.2478/v10011-012-0009-y

Becarević M, Seferović J, Ignjatović S, Singh S, Majkić-Singh N. Adiponectin, non-esterified fatty acids and antiphospholipid antibodies in type II diabetes mellitus. in Journal of Medical Biochemistry. 2012;31(3):199-204.
doi:10.2478/v10011-012-0009-y .

Becarević, Mirjana, Seferović, Jelena, Ignjatović, Svetlana, Singh, Sandra, Majkić-Singh, Nada, "Adiponectin, non-esterified fatty acids and antiphospholipid antibodies in type II diabetes mellitus" in Journal of Medical Biochemistry, 31, no. 3 (2012):199-204,
https://doi.org/10.2478/v10011-012-0009-y . .

TY  - CONF
AU  - Becarević, Mirjana
AU  - Seferović, Jelena
AU  - Ignjatović, Svetlana
AU  - Majkić-Singh, Nada
PY  - 2011
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1495
PB  - Elsevier Ireland Ltd, Clare
C3  - Atherosclerosis Supplements
T1  - Association of tnf-alpha and anticardiolipin antibodies in type ii diabetes mellitus
VL  - 12
IS  - 1
SP  - 91
EP  - 91
DO  - 10.1016/S1567-5688(11)70427-5
ER  - 

@conference{
author = "Becarević, Mirjana and Seferović, Jelena and Ignjatović, Svetlana and Majkić-Singh, Nada",
year = "2011",
publisher = "Elsevier Ireland Ltd, Clare",
journal = "Atherosclerosis Supplements",
title = "Association of tnf-alpha and anticardiolipin antibodies in type ii diabetes mellitus",
volume = "12",
number = "1",
pages = "91-91",
doi = "10.1016/S1567-5688(11)70427-5"
}

Becarević, M., Seferović, J., Ignjatović, S.,& Majkić-Singh, N.. (2011). Association of tnf-alpha and anticardiolipin antibodies in type ii diabetes mellitus. in Atherosclerosis Supplements
Elsevier Ireland Ltd, Clare., 12(1), 91-91.
https://doi.org/10.1016/S1567-5688(11)70427-5

Becarević M, Seferović J, Ignjatović S, Majkić-Singh N. Association of tnf-alpha and anticardiolipin antibodies in type ii diabetes mellitus. in Atherosclerosis Supplements. 2011;12(1):91-91.
doi:10.1016/S1567-5688(11)70427-5 .

Becarević, Mirjana, Seferović, Jelena, Ignjatović, Svetlana, Majkić-Singh, Nada, "Association of tnf-alpha and anticardiolipin antibodies in type ii diabetes mellitus" in Atherosclerosis Supplements, 12, no. 1 (2011):91-91,
https://doi.org/10.1016/S1567-5688(11)70427-5 . .

TY  - JOUR
AU  - Becarević, Mirjana
AU  - Seferović, Jelena
AU  - Ignjatović, Svetlana
AU  - Singh, Sandra
AU  - Majkić-Singh, Nada
PY  - 2011
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1552
AB  - Objective: In vitro, stimulation of monocytes with antiphospholipid (aPL) antibodies resulted in increased secretion of TNF-alpha, but association of aPL with features of diabetes mellitus is not clarified yet. Therefore, we investigated the distribution of anticardiolipin (aCL), anti-beta 2gpI (a beta 2gpI), anti-annexin A5 (aannxA5), and anti-oxLDL (aoxLDL) antibodies, and TNF-alpha in well-formed group of 78 patients with type II diabetes mellitus without vascular complications. Methods: Investigated antibodies and TNF-alpha concentrations were measured by ELISA. Results: Antiphospholipid antibodies were in positive correlation with TNF-alpha concentrations: aCL IgG (r = 0.303, p = 0.007), aCL IgM (r = 0.386, p = 0.000), a beta 2gpI IgG (r = 0.499, p = 0.000), a beta 2gpI IgM (r = 0.462, p = 0.000), aanxA5 IgG (r = 0.479, p = 0.000), aanxA5 IgM (r = 0.641, p = 0.000), aoxLDL (IgG + IgM, r = 0.279, p = 0.000). Anticardiolipin-positive and aCL-negative subgroups differed in TNF-alpha concentrations (Mann-Whitney, p = 0.032). Significantly elevated LDL concentrations were noticed in aCL-positive patients with disease duration 10-15 years (chi(2) = 15.000, p = 0.000) and apoB concentrations were elevated in aoxLDL-positive patients with disease duration 7-10 years (chi(2) = 3.938, p = 0.047). Conclusion: Significant association of antiphospholipid antibodies and TNF-alpha might be a marker of severe atherogenic profile (suggested by increased levels of lipids in aPL-positive subgroups) and should be used for the stratification of patients with an increased risk for future deterioration of the disease.
PB  - Academic Press Ltd- Elsevier Science Ltd, London
T2  - Cytokine
T1  - Significant association of antiphospholipid antibodies and TNF-alpha: Marker of severe atherogenic profile of patients with type II diabetes mellitus without micro and/or macrovascular complications
VL  - 55
IS  - 2
SP  - 301
EP  - 306
DO  - 10.1016/j.cyto.2011.05.001
ER  - 

@article{
author = "Becarević, Mirjana and Seferović, Jelena and Ignjatović, Svetlana and Singh, Sandra and Majkić-Singh, Nada",
year = "2011",
abstract = "Objective: In vitro, stimulation of monocytes with antiphospholipid (aPL) antibodies resulted in increased secretion of TNF-alpha, but association of aPL with features of diabetes mellitus is not clarified yet. Therefore, we investigated the distribution of anticardiolipin (aCL), anti-beta 2gpI (a beta 2gpI), anti-annexin A5 (aannxA5), and anti-oxLDL (aoxLDL) antibodies, and TNF-alpha in well-formed group of 78 patients with type II diabetes mellitus without vascular complications. Methods: Investigated antibodies and TNF-alpha concentrations were measured by ELISA. Results: Antiphospholipid antibodies were in positive correlation with TNF-alpha concentrations: aCL IgG (r = 0.303, p = 0.007), aCL IgM (r = 0.386, p = 0.000), a beta 2gpI IgG (r = 0.499, p = 0.000), a beta 2gpI IgM (r = 0.462, p = 0.000), aanxA5 IgG (r = 0.479, p = 0.000), aanxA5 IgM (r = 0.641, p = 0.000), aoxLDL (IgG + IgM, r = 0.279, p = 0.000). Anticardiolipin-positive and aCL-negative subgroups differed in TNF-alpha concentrations (Mann-Whitney, p = 0.032). Significantly elevated LDL concentrations were noticed in aCL-positive patients with disease duration 10-15 years (chi(2) = 15.000, p = 0.000) and apoB concentrations were elevated in aoxLDL-positive patients with disease duration 7-10 years (chi(2) = 3.938, p = 0.047). Conclusion: Significant association of antiphospholipid antibodies and TNF-alpha might be a marker of severe atherogenic profile (suggested by increased levels of lipids in aPL-positive subgroups) and should be used for the stratification of patients with an increased risk for future deterioration of the disease.",
publisher = "Academic Press Ltd- Elsevier Science Ltd, London",
journal = "Cytokine",
title = "Significant association of antiphospholipid antibodies and TNF-alpha: Marker of severe atherogenic profile of patients with type II diabetes mellitus without micro and/or macrovascular complications",
volume = "55",
number = "2",
pages = "301-306",
doi = "10.1016/j.cyto.2011.05.001"
}

Becarević, M., Seferović, J., Ignjatović, S., Singh, S.,& Majkić-Singh, N.. (2011). Significant association of antiphospholipid antibodies and TNF-alpha: Marker of severe atherogenic profile of patients with type II diabetes mellitus without micro and/or macrovascular complications. in Cytokine
Academic Press Ltd- Elsevier Science Ltd, London., 55(2), 301-306.
https://doi.org/10.1016/j.cyto.2011.05.001

Becarević M, Seferović J, Ignjatović S, Singh S, Majkić-Singh N. Significant association of antiphospholipid antibodies and TNF-alpha: Marker of severe atherogenic profile of patients with type II diabetes mellitus without micro and/or macrovascular complications. in Cytokine. 2011;55(2):301-306.
doi:10.1016/j.cyto.2011.05.001 .

Becarević, Mirjana, Seferović, Jelena, Ignjatović, Svetlana, Singh, Sandra, Majkić-Singh, Nada, "Significant association of antiphospholipid antibodies and TNF-alpha: Marker of severe atherogenic profile of patients with type II diabetes mellitus without micro and/or macrovascular complications" in Cytokine, 55, no. 2 (2011):301-306,
https://doi.org/10.1016/j.cyto.2011.05.001 . .